	FG W AHAC
FORM PTO-1449	SERIAL NO. 09/708,276 CASE NO. 8642/94
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 7, 2000  GROUP ART UNIT  (636
(use several sheets if necessary)	APPLICANT(S):

U.S. PATENT DOCUMENTS REFERENCE DESIGNATION

REFERENCE DESIGNATION		0.0. I AI E	11 DOCCINEITIO			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
90	A1	5,863,904	1/26/99	Nabel et al.	<del>-514/44</del>	
- ZX	A2	5,672,508	09/30/97	Gyuris et al.	<del>435/320:1</del>	
	A3					
	A4					
-	A5					
	A6					
	A7					
	A8					
	A9					
	A10					
	A11					
	A12					
	A13					

**FOREIGN PATENT DOCUMENTS** 

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSI YES	ATION NO
139	A14	WO 95/18824	7-13-95	WO	-514/44		
	A15	WO 96/25507	8-22-96	WO	435/320.1		
17	A16	WO 9602140A1	02/1996	PCT			
	A17						
	A18						

EXAMINER	I		
INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
0	A19	PCT Notification of Transmission of The International Search Report or the Declaration (8 pages), Mailed 1/14/99.	
91	A20	Chen et al., "Downregulation of Cyclin-dependent Kinase 2 Activity and Cyclin A Promoter Activity in Vascular Smooth Muscle Cells by p27 KIP1, an Inhibitor of Neointima Formation in the Rat Caroid Artery," pp. 2234-2341, J. Clin. Invest. 99 (10) 1997.	
M	A21	Toyoshima et al., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell, Vol. 78, 7/15/94, pp. 67-74.	
90	A22	Tanner et al., "Expression of Cyclin-Dependent Kinase Inhibitors in Vascular Disease," pp. 396-403. Circ. Res. 1998: Vol. 82.	
ay	A23	Tanner et al., "Gene Transfer of p27 KIP2 and p21 CIP1 Cyclin-Dependent Kinase Inhibitors, But Not p16 INK, Negatively Regulate VSMC Proliferation Through Differential Effects on Kinase Activity," Circulation Vol. 96(8): SUPPL. Pg. I5 10/97.	

EXAMINER WHI Cantel	DATE CONSIDERED 3/16/0~

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

		Page 2 of 2
FORM PTO-1449	SERIAL NO. 09/708,276	CASE NO. 8642/94
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 7, 2000	GROUP ART UNIT.
(use several sheets if necessary)	APPLICANT(S):	JAN 2 9 2001

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
Bh	A24	Braun-Dullaeus et al., "Regulation of Vascular Smooth Muscle Cell Proliferation by the Cyclin- Dependent Kinase Inhibitor p27 KIP1, one page J. Invest. Med., Vol. 45(3) p. 224A 3/97.
M	A25	Hideo Toyoshima and Tony Hunter, "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21", Cell. Vol. 78, pp. 67-74, July 15, 1994.
M	A26	Mediator of Extracellular Antimitogenic Signals", Cell, Vol. 78, pp. 59-66, July 15, 1994.
M	A27	Steve Coats et al., "Requirement of p 27 KIP1 for Restriction Point Control of the Fibroblast Cell Cycle", Science, Vol. 272, May 10, 1996, pp. 877-880.
an	A28	Koyama et al. Fibrillarcollagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors, Cell, Vol. 87, 1069-1078, December 13, 1996.

EXAMINER	William Sandals	DATE CONSIDERED 3/16/02